Novo Nordisk: Valuations Are Blind To The Upside (NYSE:NVO)
· seekingalpha.com
Novo Nordisk's Q3 2026 beat and overlooked guidance upgrades make medium-term de-rating exceedingly unlikely. Click for more on the NVO stock.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...